Top Page
Pharmaust Limited
(Sydney:NUZ)
Pharmaust Limited (NUZ) vs. iShares MSCI Australia ETF (EWA)
Pharmaust Limited Business Overview & Revenue Model
Pharmaust Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 857.35K | 0.00 | 0.00 | 2.82M | 3.38M | 3.38M |
| Gross Profit | 855.71K | 0.00 | -1.64K | -929.53K | -223.52K | 3.07M |
| EBITDA | -9.45M | -18.48M | -9.45M | -9.45M | -1.30M | -1.30M |
| Net Income | -7.69M | -16.59M | -9.03M | -9.03M | -1.71M | -1.71M |
Balance Sheet | ||||||
| Total Assets | 11.12M | 4.36M | 11.12M | 6.13M | 6.13M | 10.08M |
| Cash, Cash Equivalents and Short-Term Investments | 9.72M | 4.18M | 9.72M | 2.71M | 2.71M | 3.02M |
| Total Debt | 0.00 | 0.00 | 0.00 | 1.05M | 1.05M | 1.28M |
| Total Liabilities | 896.61K | 1.54M | 896.61K | 2.24M | 2.23M | 2.23M |
| Stockholders Equity | 10.23M | 2.82M | 10.23M | 3.89M | 7.84M | 8.88M |
Cash Flow | ||||||
| Free Cash Flow | -5.17M | -14.29M | -5.17M | -1.60M | -1.38M | -1.08M |
| Operating Cash Flow | -5.17M | -14.29M | -5.17M | -1.56M | -1.33M | -937.97K |
| Investing Cash Flow | -1.17M | -21.55K | -1.17M | -34.93K | -43.38K | -138.04K |
| Financing Cash Flow | 13.34M | 8.76M | 13.34M | 1.89M | 770.99K | 1.22M |
Pharmaust Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$190.86M | -7.27 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$88.33M | -8.79 | -49.72% | ― | ― | 10.78% | |
44 Neutral | AU$80.46M | -2.75 | -247.98% | ― | ― | ― | |
44 Neutral | AU$106.91M | -12.50 | -47.98% | ― | 700.00% | 26.88% |
Pharmaust Limited Corporate Events
Neurizon Therapeutics has reported a change in the holdings of director Dr Michael Thurn, who maintains both direct and indirect interests in the company through family accounts and personal holdings of shares, options and performance rights. The notice confirms the lapse or disposal of 1,000,000 unlisted options expiring on 19 January 2026 at $0.175, with no consideration received, leaving Dr Thurn’s remaining interests concentrated in fully paid ordinary shares, listed options, longer-dated unlisted options and performance rights, and signalling a modest simplification of his short‑dated derivative exposure without altering his substantial alignment with shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has called a virtual-only General Meeting of shareholders for 20 February 2026 at 2:00pm AEDT, to be held via an online meeting platform, with all meeting materials, including the Notice of Meeting and explanatory statement, provided electronically through the company’s website, share registry portal, and ASX announcements page. The move underscores Neurizon’s shift away from physical mailouts toward digital communication, streamlining shareholder engagement and voting processes while encouraging investors to update their communication preferences, submit proxies ahead of the meeting, and utilise online channels for access and participation, which may enhance accessibility and reduce administrative costs for the company and its stakeholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has secured registered trademark protection for the NEURIZON brand across its key global commercial markets, including the United States, European Union, United Kingdom, Australia and Japan, covering pharmaceutical research and development, clinical trial services and neurological therapeutics. The completion of this global trademark portfolio, particularly the US registration in Neurizon’s primary long-term commercialisation market, strengthens the company’s intellectual property framework alongside patent protection for lead asset NUZ-001, supports consistent global brand deployment and enhances strategic flexibility for future partnerships or independent commercialisation as it advances towards later-stage clinical development.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has released an investor webinar presentation outlining recent strategic and operational progress, including a strengthened funding position, regulatory developments and preparations to commence patient enrolment in the HEALEY ALS Platform Trial. The presentation details the company’s clinical strategy for lead asset NUZ-001, key near-term milestones and execution priorities for calendar year 2026, signalling an important phase of clinical and corporate execution that could influence its positioning in the ALS treatment landscape and its engagement with existing and prospective investors.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has scheduled a shareholder webinar for 15 January 2026 to brief investors on the execution of recent funding initiatives, regulatory developments and upcoming operational milestones related to its participation in the HEALEY ALS Platform Trial. The event, led by CEO and Managing Director Dr Michael Thurn and other team members, will include a Q&A session, require prior registration, and will be recorded for later viewing, underscoring the company’s effort to increase transparency and engagement with investors as it advances its lead ALS drug candidate through key clinical and regulatory inflection points.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has reported the expiry of 3 million unlisted options exercisable at $0.15 that were due to lapse on 31 December 2025, with none of these options being exercised before their expiry. The cessation of these securities reduces the pool of potential future share dilution for existing investors and marginally simplifies the company’s capital structure, though it does not immediately alter the number of shares on issue or directly affect day-to-day operations.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has opened a pro-rata non-renounceable entitlement offer to raise up to approximately A$17.1 million before costs, giving eligible shareholders the right to subscribe for two new shares for every five held at an offer price of A$0.08 per share, based on a record date of 30 December 2025. The capital raising, which runs from 5 to 21 January 2026 under an ASX-compliant timetable, is expected to bolster the company’s funding base as it advances clinical development of its ALS candidate NUZ-001 and supports its broader ambitions in neurodegenerative disease, with the structure of the offer providing existing investors an opportunity to maintain their ownership position.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has issued 79,330,864 fully paid ordinary shares at $0.08 per share to sophisticated and professional investors under a placement first announced in late December 2025. The company has confirmed the shares were issued without a prospectus under the Corporations Act’s cleansing provisions and that it remains compliant with its continuous disclosure and financial reporting obligations, with no excluded information outstanding, effectively clearing the way for secondary trading of the new stock and reinforcing regulatory transparency for shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has provided a regulatory update on NUZ-001, its investigational ALS therapy, confirming that the US FDA has declined its initial Fast Track Designation request but offered detailed feedback on the additional clinical data needed to demonstrate differentiation from existing approved treatments. The company views this as a clear regulatory pathway and plans to generate the requested evidence as NUZ-001 progresses, potentially enabling a renewed Fast Track application and influencing its long-term positioning in the competitive ALS drug development landscape.
Operationally, NUZ-001 has advanced within the HEALEY ALS Platform Trial into key start-up phases, with IRB submissions, site activations and related activities underway, and first patient enrolment expected very early this year, underpinned by recently secured funding sufficient to complete the pivotal registration-adaptive Phase 2/3 study. Participation in the large, multicentre HEALEY platform, designed to accelerate ALS drug development via shared infrastructure and adaptive trial design, gives Neurizon an efficient route to generate robust clinical data, which is critical for future regulatory interactions and value creation for patients, investors and partners.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s interests, with Duchini, through Kelbury Pty Ltd, acquiring 416,667 fully paid ordinary shares at $0.12 per share in a recent placement. Following the transaction, his indirect holding increased to 1,732,456 shares while his direct holding of 960,000 unlisted options remained unchanged, signalling continued insider support for the company’s capital raising efforts and potentially reinforcing market confidence in its strategic direction.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has applied to the ASX for quotation of 79,330,864 new ordinary fully paid shares, to be issued on 2 January 2026 under code NUZ. The application, lodged as an Appendix 2A, indicates a significant expansion of the company’s quoted share capital, which may influence market liquidity and ownership structure and is linked to transactions previously flagged in an earlier Appendix 3B filing.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has issued 1,083,335 fully paid ordinary shares to participating directors from its September 2025 placement at $0.12 per share, following shareholder approval at the company’s November 2025 annual general meeting. The company confirmed the shares were issued without a prospectus under the Corporations Act cleansing provisions and stated it is up to date with its financial reporting and continuous disclosure obligations, with no excluded information, ensuring the new securities can trade freely and signaling continued alignment between the board and shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has launched a pro-rata non-renounceable entitlement offer to raise up to approximately $17.1 million before costs, giving eligible shareholders the right to subscribe for two new shares for every five held at an issue price of $0.08 per share, based on a record date of 30 December 2025. The offer will be conducted without a prospectus under Australia’s cleansing notice provisions, with the company confirming compliance with continuous disclosure obligations and stating that, given the pro-rata structure and current substantial holdings, the capital raising is not expected to have any material impact on the control of the company, thereby providing additional funding with limited governance disruption for existing investors.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has announced a proposed capital raising involving the issue of up to 3,314,000 convertible notes and 25,000,000 new fully paid ordinary shares via a placement or similar structure. The proposed issuance, scheduled for 17 February 2026, is designed to strengthen the company’s balance sheet and provide funding flexibility for its therapeutic development programs, potentially diluting existing shareholders but supporting Neurizon’s ability to advance its pipeline and maintain its position in the competitive biotech market.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has announced a proposed non-renounceable pro rata issue of up to 214,315,640 new ordinary fully paid shares, alongside a separate placement or other type of issue of up to 89,080,864 shares, as part of a broader capital-raising initiative. The staged timetable, with key dates spanning late December 2025 to late January 2026, signals a substantial expansion of the company’s equity base, which may provide additional funding capacity for its therapeutic programs while diluting existing holdings, and underscores management’s reliance on the equity markets to support ongoing development and growth plans.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has launched an equity raising comprising a placement of new fully paid ordinary shares to eligible institutional, sophisticated and professional investors, alongside a non-renounceable entitlement offer of new shares to existing eligible shareholders. The offer, which is not underwritten and may be varied or withdrawn at the company’s discretion, is being managed by Morgans Corporate Limited and includes the potential placement of any shortfall shares within three months of the entitlement offer’s close, with allocations determined by Neurizon to support an informed and liquid trading market and a broad, long-term shareholder base.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has secured a comprehensive funding package to support its participation in the HEALEY ALS Platform Trial for its lead drug candidate NUZ-001, a pivotal adaptive Phase 2/3 registration study in ALS. The package comprises approximately $7.1 million raised via a discounted share placement to new and existing sophisticated investors, a proposed 2-for-5 non-renounceable entitlement offer to raise up to a further $17.1 million, and a $20 million convertible note facility from New York-based Obsidian Global GP, structured to provide milestone-aligned capital over two years while limiting upfront dilution. Together with existing cash and expected R&D tax rebates, the funding underpins both the randomized and extension phases of the HEALEY trial and extends Neurizon’s capital runway, enabling it to advance NUZ-001 through late-stage clinical development, pursue accelerated regulatory pathways, build broader commercial and partnering opportunities, and explore the drug’s potential as a platform therapy across multiple neurodegenerative indications, which management says fundamentally strengthens the company’s balance sheet and long-term value proposition for shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has requested and been granted a trading halt on its ordinary shares and listed options on the ASX, effective from 19 December 2025, as it prepares to announce the outcome of a proposed capital raising. The halt, which is intended to help the company manage its continuous disclosure obligations, will remain in place until either the announcement is released or normal trading resumes on 23 December 2025, signaling that a potentially significant funding development is imminent for investors and other stakeholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has announced that the US FDA has cleared its drug regimen, NUZ-001, for entry into the HEALEY ALS Platform Trial. This clearance marks a significant regulatory milestone for Neurizon, allowing the company to proceed with clinical activities aimed at developing a new treatment for ALS. The trial, which is a multicenter, double-blind, placebo-controlled, adaptive trial, aims to accelerate the development of potential new ALS therapies. The clearance is expected to enhance Neurizon’s position in the industry and bring it closer to addressing the unmet medical needs of ALS patients.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has amended its Constitution following approval by shareholders at the Annual General Meeting. This amendment aligns with the company’s strategic focus on advancing treatments for neurodegenerative diseases, potentially impacting its operations and positioning within the biotech industry. The changes reflect Neurizon’s commitment to enhancing its governance framework as it continues to develop innovative therapies for ALS and other neural disorders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited announced the results of its Annual General Meeting, detailing resolutions and proxies received. The company continues to focus on its strategic goal of advancing treatments for neurodegenerative diseases, particularly through its lead drug candidate, NUZ-001, for ALS. This announcement underscores Neurizon’s commitment to addressing complex neural disorders and enhancing its position in the biotechnology industry.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited, a company focused on neurodegenerative diseases, presented at their AGM with insights into their future strategies and expectations. The presentation highlighted the company’s intentions and plans, though it noted that these are subject to risks and uncertainties, which may impact the actual outcomes. Stakeholders are advised to consider these factors when evaluating the company’s future performance.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has made significant progress over the past year, including lifting the FDA clinical hold on its drug NUZ-001 and preparing to enter the HEALEY ALS Platform Trial. The company has strengthened its governance with the appointment of Ms. Justine Conway as a Board Observer, enhancing strategic insight as Neurizon moves towards late-stage development and commercialization. Key achievements include advancements in preclinical and clinical programs, securing a global license agreement with Elanco, and completing a $5.2 million placement to support its strategic initiatives. Neurizon’s four-pillar strategy focuses on accelerating patient access, driving clinical progress, broadening therapeutic impact, and ensuring commercial readiness.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has appointed Ms. Justine Conway, Global Head of Business Development at Elanco Animal Health, as a Board Observer. This appointment underscores the strong partnership between Neurizon and Elanco, following a global license agreement for Monepantel, the active ingredient in NUZ-001. The agreement supports Neurizon’s regulatory foundations and provides access to critical data for future clinical trials and potential global market entry. Ms. Conway’s extensive experience in healthcare and strategic partnerships is expected to enhance Neurizon’s governance and aid in advancing NUZ-001 towards late-stage development and global commercialization.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has issued 150,000 fully paid ordinary shares following the exercise of unlisted options at an exercise price of $0.10 each. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions. This move is part of Neurizon’s broader strategy to enhance its financial position as it continues to develop its lead drug candidate, NUZ-001, for ALS treatment, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has announced the application for the quotation of 150,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code NUZ. This move is part of the company’s strategy to enhance its capital structure and market presence, potentially impacting its operations and positioning within the industry.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited announced a webinar to update shareholders on its Q1 FY2026 results and progress in advancing NUZ-001 towards the HEALEY ALS Platform Trial. The company has successfully submitted and received acceptance from the U.S. FDA to lift the clinical hold, allowing entry into the trial. Neurizon has strengthened its financial position with a $5.2 million share placement and a $1.5 million secured loan. The company is also expanding global engagement by participating in industry conferences to build relationships with potential partners and the ALS community.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has achieved significant milestones, including the FDA lifting the clinical hold on NUZ-001, allowing entry into the HEALEY ALS Platform Trial. The company has also secured a global licensing agreement with Elanco Animal Health and initiated GMP manufacturing of NUZ-001. Financially, Neurizon raised $5.2 million through a share placement and received a $1.5 million loan, enhancing its financial position. Additionally, the company was awarded an Advance and Overseas Finding from AusIndustry, enabling a cash rebate on eligible overseas R&D expenditures. These developments position Neurizon to accelerate NUZ-001’s regulatory approval process and enhance its market visibility, particularly in the U.S.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.